Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Shopify

These two stocks will reward investors who are in it for the long haul.

Got $5,000? Smart Investors Are Piling Into These Stocks

These three nonprofits are making a difference where it’s needed the most.

These 3 Patient Advocacy Groups Are Helping Solve Issues in the COVID-19 Pandemic

Bristol Myers (BMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bristol Myers (BMY) Moves to Strong Buy: Rationale Behind the Upgrade

Bristol-Myers Squibb’s stock has declined 2% since early February after the WHO declared the coronavirus a global health emergency, while Amgen stock has fared much better and gained 19% of its value. The spread of Covid-19 in various parts of the world has had a negative impact on the pharma.

Is Bristol-Myers Squibb A Better Bet Than Amgen?

Kadmon Hlds

Protagonist Therapeutics

Pharmaceutical stocks dipped by a single-digit percentage in the first six months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.

Why These 3 Pharma Stocks Are Outplaying 90% Of The Stock Market

Bristol Myers stock has slipped this year. But the addition of Celgene has helped bolster the pharmaceutical company's sales.

Bristol Myers Just Launched A New MS Drug — But Is BMY Stock A Buy?

Delek Logistics Partners

Gilead Sciences

Kroger

Vale S.A.

Earnings yield is very important in comparing a stock with other stocks and with fixed income securities. A stock with higher earnings yield fetches better returns.

5 High Earnings Yield Stocks for a Winning Portfolio

Bristol-Myers Squibb: Growth And Valuation Trump Other Concerns

BMY director Paliwal purchased $500K of shares. There is a high probability of strong returns given that BMY is picked by our formula and the historical performance of BMY insiders.

Bristol Myers Squibb: Insider Anticipating Significant Shareholder Value Creation From Merger

Blackrock Inc

Procter & Gamble

Raytheon Technologies

After the huge melt-up rally off the March lows, the S&P 500 closed Wednesday at 3,115.

Q2 Earnings Will Be Gruesome and COVID Is Back: Rotate to Defensive Dividend Stocks

Celgene

Investors and analysts who questioned the wisdom of Bristol-Myers Squibb Co.’s (NYSE:BMY) purchase of Celgene last year for $74 billion might want to reconsider their opinion about the largest health care takeover in history.

Celgene Deal Starting to Pay Off Big for Bristol-Myers

Amgen

Anthem

Guardant Health Inc

Iovance Biotherapeutics

IQVIA Hlds

Medtronic

Veeva Systems

West Pharmaceutical Services

Acceleron Pharma

The pandemic has put the health care industry under a global spotlight.

10 Stocks to Invest in the Health Care Revolution

BMY vs. AZN: Which Stock Is the Better Value Option?

BMY or AZN: Which Is the Better Value Stock Right Now?

Chevron

D.R. Horton

Darden Restaurants

With the Dow and the S&P 500 booking their best quarterly performance since 1987, one could consider stepping into the markets again with an investment perspective.

Markets Book Best Quarterly Gains in 20 Years: 4 Stocks to Buy

Lam Research

QUALCOMM

ResMed

UnitedHealth Group

Given strong dividend growth and big money signals, these stocks could be worth a spot in a yield-oriented portfolio.

Best Dividend Stocks for July 2020

AbbVie

AstraZeneca

Eli Lilly

Novartis

Pfizer

The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade.

Canada federal court dismisses drugmakers' plea challenging drug price rules

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Bristol Myers Squibb (BMY) a Great Value Stock Right Now?

Bristol Myers (BMY) and partner Acceleron win EC approval of Reblozyl (luspatercept) for two indications.

Bristol Myers & Acceleron Obtain EC Approval for Reblozyl

These drugmakers' businesses shouldn't be significantly impacted by an economic downturn.

3 Top Pharma Stocks to Buy in a Recession

Bristol Myers Squibb has been aggressively cutting costs to adapt to its scale following patent losses, which we believe will help open up capital for reinvestment in the business.

5 Reasons Bristol Myers Squibb Is An Exceptional Blue-Chip For Retirees

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Special Call (Transcript)

Capri Holdings Ltd

Dell Technologies

Dollar Tree

LM Ericsson Telefon

Knoll

MCBC Hlds

Photronics

Value stocks have been out of favor for some time — but that will change at some point. When it does, these 10 names should be winners.

10 Value Stocks to Keep on Your Short List

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Hosts Investor Series - Hematology Conference Call (Transcript)

3 Reasons Bristol-Myers Squibb Could Make You Rich

Here's why this cheap blue-chip pharma stock is a solid buy for dividend, value, and growth investors alike.

News for Bristol-Myers Stock (BMY)